Effective March 2, 2022, the GT Biopharma, Inc. (Registrant) appointed Michael Breen as the Registrant's Interim Chief Executive Officer with an increase in his annual base compensation to $515,000. Gregory Berk, M.D. ceased serving as the Registrant's Interim Chief Executive Officer, but will continue to serve as the Registrant's President of Research & Development and Chief Medical Officer, with a cost-of-living increase in his annual base compensation to $437,750.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.8 USD | +1.82% |
|
-1.06% | -63.40% |
Jun. 27 | GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650 | MT |
Jun. 27 | GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study | DJ |
1st Jan change | Capi. | |
---|---|---|
-63.40% | 5.93M | |
+56.60% | 809B | |
+39.52% | 624B | |
-7.18% | 351B | |
+7.16% | 289B | |
+13.74% | 240B | |
+13.83% | 220B | |
-0.49% | 219B | |
+8.32% | 166B | |
-2.88% | 157B |
- Stock Market
- Equities
- GTBP Stock
- News GT Biopharma, Inc.
- GT Biopharma, Inc. Announces CEO Changes